Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 2, 2002, Pages 209-219

  Kurata, Yasuo ^a,b,c   Ieiri, Ichiro ^a,b,c   Kimura, Miyuki ^a,b,c   Morita, Toshihiro ^a,b,c   Irie, Shin ^a,b,c   Urae, Akinori ^a,b,c   Ohdo, Shigehiro ^a,b,c   Ohtani, Hisakazu ^a,b,c   Sawada, Yasufumi ^a,b,c   Higuchi, Shun ^a,b,c   Otsubo, Kenji ^a,b,c  

^a KYUSHU UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c Kyushu Clinical Pharmacology Research Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DIGOSIN; DIGOXIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ALLELES; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CARDIOTONIC AGENTS; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME SYSTEM; DIGOXIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME INHIBITORS; GENES, MDR; GENOTYPE; HUMANS; INJECTIONS, INTRAVENOUS; JAPAN; MALE; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REFERENCE VALUES;

EID: 0036693051     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.126177     Document Type: Article

References (52)

1. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
2. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoprotein in mammals
3. Expression of a multidrug-resistance gene in human tumors and tissues
4. Cellular location of the multidrug resistance gene product P-glycoprotein in normal human tissues
5. Tissue distribution of P-glycoprotein encoded by a multidrug-resistance gene as revealed by a monoclonal antibody, MRK16
6. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues
7. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
8. Function of P-glycoprotein expressed in placenta and mole
9. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
10. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoprotein
11. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
12. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein
13. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
14. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
15. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted
16. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measures in mice with an mdr1a gene disruption
17. Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice
18. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice
19. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporin
20. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
21. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects
22. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
23. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene
24. Identification of functionally variant MDR1 alleles among European Americans and African Americans
25. Energy-dependent transport of digoxin across renal tubular cell monolayers (LLC-PK1)
26. P-glycoprotein-mediated renal tubular secretion of digoxin: The toxicological significance of the urine-blood barrier model
27. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin
28. Digoxin
29. Toxic digoxin-drug interactions: The major role of renal P-glycoprotein
30. Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein
31. Inhibition of P-glycoprotein-mediated drug transport
32. Cyclosporin and quinidine inhibition of renal digoxin excretion: Evidence for luminal secretion of digoxin
33. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1)
34. Cyclosporin and quinidine inhibition of renal digoxin excretion: Evidence for luminal secretion of digoxin
35. Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney
36. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
37. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil
38. P-glycoprotein gene (MDR1) cDNA from human adrenal: Normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance
39. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells
40. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A through concentrations or rejection incidence in stable renal transplant recipients
41. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects
42. Clarithromycin-related toxic effects of digoxin
43. Clarithromycin-associated digoxin toxicity in the elderly
44. Digoxin toxicity secondary to clarithromycin therapy
45. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney
46. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein
47. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19
48. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole
49. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporin A
50. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: Possible relationship to intestinal P-glycoprotein activity
51. MDR1 pharmacokinetics: Frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity
52. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects